ORG Wealth Partners LLC Has $144,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

ORG Wealth Partners LLC decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 36.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 633 shares of the medical instruments supplier’s stock after selling 363 shares during the quarter. ORG Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $144,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company during the third quarter worth $26,000. Ashton Thomas Securities LLC bought a new stake in Becton, Dickinson and Company during the third quarter worth about $33,000. Tompkins Financial Corp lifted its position in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 46 shares during the period. Sound Income Strategies LLC lifted its position in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Abound Wealth Management lifted its position in Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the sale, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,747 shares of company stock valued at $1,949,520 in the last ninety days. 0.36% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $233.65 on Friday. The stock has a market cap of $67.76 billion, a P/E ratio of 39.34, a P/E/G ratio of 1.64 and a beta of 0.39. The business’s fifty day moving average is $226.91 and its 200 day moving average is $232.45. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the firm posted $3.42 EPS. Becton, Dickinson and Company’s quarterly revenue was up 6.9% compared to the same quarter last year. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were given a dividend of $1.04 per share. The ex-dividend date was Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.78%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.